Abstract CT121: ARX517, an anti-PSMA ADC targeting mCRPC resistant or refractory to standard therapies: A phase 1 dose escalation and dose expansion study (ARX517-2011, NCT04662580)
Overview of attention for article published in Cancer Research, April 2023
Altmetric Attention Score: 3
About this Attention Score
-
Above-average Attention Score compared to outputs of the same age (59th percentile)
-
Average Attention Score compared to outputs of the same age and source
Readers on
- mendeley
- 4 Mendeley